menstrual migraine

News

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual migraine.

Oncology

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.